What’s happening at InnoCore?

InnoCore Pharmaceuticals today announced a formulation development partnership with an undisclosed North American pharmaceutical company to advance a peptide therapeutic designed to support improved metabolic and glucose-control outcomes, potentially relevant to conditions such as Type 1 diabetes.

InnoCore Pharmaceuticals today announced a new formulation development project with a returning global pharmaceutical partner, building on a successful history of collaboration.

InnoCore Pharmaceuticals today announced the expansion of an ongoing formulation development program with a returning undisclosed global Top 10 pharmaceutical company.

InnoCore Pharmaceuticals has launched its new business strategy based on its proprietary best-in-class polymeric drug delivery platform, SynBiosys®.

Innocore has been awarded an EU grant and Joins Research Consortium focused in brain diseases withh argeted drug delivery across the blood-brain barrier.

InnoCore joins OAinject consortium to develop new therapies for osteoarthritis

Data published in scientific journal.

AndroSphere™ Extended Release hCG Microspheres for Treatment of Hypogonadotropic Hypogonadism

InnoCore Pharmaceuticals has secured funding from the European Regional Development Fund to develop a biodegradable polymer-based microneedle array patch.